Coherus BioSciences Inc (CHRS) — Cash Flow-to-Debt Ratio
Coherus BioSciences Inc (CHRS) has a Cash Flow-to-Debt Ratio of -0.10x as of December 2025, meaning its operating cash flow of $-19.72 Million could theoretically repay 0% of its total liabilities ($197.33 Million) in one year. See Coherus BioSciences Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Coherus BioSciences Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Coherus BioSciences Inc across 14 annual periods. Also explore Coherus BioSciences Inc (CHRS) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Coherus BioSciences Inc (2012–2025)
Year-by-year debt coverage analysis for Coherus BioSciences Inc. For market capitalisation and broader financial context, see Coherus BioSciences Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.70x | $-138.51 Million | $197.33 Million | ▼ -1893.6% |
| 2024 | -0.04x | $-20.44 Million | $580.52 Million | ▲ +83.4% |
| 2023 | -0.21x | $-174.88 Million | $823.03 Million | ▲ +45.5% |
| 2022 | -0.39x | $-241.12 Million | $618.26 Million | ▼ -506.0% |
| 2021 | -0.06x | $-37.43 Million | $581.61 Million | ▼ -123.4% |
| 2020 | 0.27x | $154.15 Million | $560.67 Million | ▲ +194.5% |
| 2019 | 0.09x | $28.36 Million | $303.71 Million | ▲ +108.1% |
| 2018 | -1.15x | $-159.27 Million | $138.06 Million | ▲ +23.9% |
| 2017 | -1.52x | $-200.29 Million | $132.08 Million | ▲ +4.4% |
| 2016 | -1.59x | $-252.54 Million | $159.13 Million | ▼ -222.3% |
| 2015 | -0.49x | $-107.99 Million | $219.31 Million | ▼ -147.9% |
| 2014 | -0.20x | $-23.93 Million | $120.46 Million | ▼ -215.7% |
| 2013 | 0.17x | $15.42 Million | $89.83 Million | ▲ +116.3% |
| 2012 | -1.05x | $-18.25 Million | $17.34 Million | — |